Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma

Table 1 Physiological characteristics of hepatocellular carcinoma patients (n = 162)

	n (%)
Sex
Female	15 (9.3)
Male	147 (90.7)
Age (yr)
< 48	77 (47.5)
≥ 48	85 (52.5)
HBV infection1
-	21 (13.0)
+	140 (86.4)
HCV infection
-	158 (97.5)
+	4 (2.5)
GGT (U/L)2
< 50	45 (27.8)
50-99	48 (29.6)
≥ 100	67 (41.4)
AFP (ng/mL)
< 20	53 (32.7)
20-399	45 (27.8)
≥ 400	64 (39.5)
Tumor size (cm)
< 5	53 (32.7)
≥ 5	109 (67.3)
Ascites3
-	148 (91.4)
+	14 (8.6)
Cirrhosis
Total	19 (11.7)
Mild	80 (49.4)
Moderate	49 (30.2)
Severe	14 (8.6)
Edmondson grade
I	11 (6.8)
II	71 (43.8)
III	77 (47.5)
IV	3 (1.9)
TNM stage
I	106 (65.4)
II	7 (4.3)
III	49 (30.3)
G-1666A genotype
AA	55 (34.0)
AG	89 (54.9)
GG	18 (11.1)

¹(-) absence, (+) presence, one case unconfirmed;

²Two cases unconfirmed;

³(-) absence, (+) presence. HBV: Hepatitis B virus; HCV: Hepatitis C virus; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein.